Dr. Reddy's Laboratories Limited (NSE:DRREDDY)
India
· Delayed Price · Currency is INR 1,275.20
-2.40 (-0.19%)
At close: Dec 5, 2025
Dr. Reddy's Laboratories Revenue
Dr. Reddy's Laboratories had revenue of 88.05B INR in the quarter ending September 30, 2025, with 9.84% growth. This brings the company's revenue in the last twelve months to 342.15B, up 14.10% year-over-year. In the fiscal year ending March 31, 2025, Dr. Reddy's Laboratories had annual revenue of 325.54B with 16.61% growth.
Revenue (ttm)
342.15B
Revenue Growth
+14.10%
P/S Ratio
3.10
Revenue / Employee
12.30M
Employees
27,811
Market Cap
1,061.51B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 325.54B | 46.37B | 16.61% |
| Mar 31, 2024 | 279.16B | 33.29B | 13.54% |
| Mar 31, 2023 | 245.88B | 31.49B | 14.69% |
| Mar 31, 2022 | 214.39B | 24.67B | 13.00% |
| Mar 31, 2021 | 189.72B | 15.12B | 8.66% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 549.64B |
| Divi's Laboratories | 100.29B |
| Cipla | 279.66B |
| Apollo Hospitals Enterprise | 232.65B |
| Zydus Lifesciences | 244.94B |
| Mankind Pharma | 135.46B |
| Aurobindo Pharma | 325.14B |
| Fortis Healthcare | 84.37B |
Dr. Reddy's Laboratories News
- 1 day ago - JSW Steel, Kotak Mahindra & more: Top stocks to buy today — Check list - The Times of India
- 3 days ago - Dr Reddys, Titan & more: Top stocks to buy on December 3 — Check list - The Times of India
- 3 days ago - Dr Reddy’s can make Novo’s weight loss drug, rules HC - The Times of India
- 3 days ago - Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies - Business Wire
- 4 days ago - Nifty 50 top gainers today, December 2: Asian Paints, Dr. Reddy’s Laboratories, Maruti Suzuki India, Bharti Airtel and more - Business Upturn
- 10 days ago - Dr. Reddy’s Laboratories arm Aurigene Oncology receives GST appellate order - Business Upturn
- 11 days ago - Biosimilar push: Dr Reddy’s gets EU nod for denosumab copy; Prolia, Xgeva rivals set for rollout - The Times of India
- 12 days ago - Dr. Reddy’s Laboratories receives European Commission approval for AVT03 - Business Upturn